Merrimack Pharmaceuticals Announces Positive MM-398 Results and AT&T May Acquire DIRECTV

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) announced that  MM-398, the company's late-stage pancreatic cancer therapy that is given to patients who've previously been treated with Gemzar, had met its primary endpoint of overall survival. The company issued a press release stating that the combination of MM-398 with 5-flouroacil and leucovorin delivered an overall survival of 6.1 months, which was an improvement of 1.9 months compared to the placebo of 5-flouroacil and leucovorin alone which achieved only 4.2 months of overall survival. Furthermore, a hazard ratio of 0.67 implied a 33%